· Circio scientists were invited to co-author a review article on the
therapeutic potential of synthetic circular RNA and vector-based circular RNA
expression
  · The article describes properties, technologies, applications, opportunities
and challenges for circular RNA-based therapeutics
  · The review was published on 9 January 2025 in the prestigious high-impact
journal Nature Reviews Genetics, which has an impact-factor of 39.1

Oslo, Norway 13 January 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, today announces that Circio scientists have been invited to co
-author a review article summarizing the circular RNA field. The review is
entitled "The therapeutic potential of circular RNAs" and was published in the
prestigious scientific journal Nature Reviews Genetics on 9 January 2025.

Over the past decade, circular RNAs (circRNAs) have demonstrated to the
scientific community their unique properties and enhanced stability. This has
made them of significant interest as a format for the development of novel
future therapeutics. This review article describes the current state of circRNA
therapeutics, highlighting key advancements and opportunities while addressing
challenges in the field.

Specifically, the review highlights the therapeutic potential of circRNA
technologies in a variety of indications, including infectious diseases, CAR-T
therapy, and gene therapy. It emphasizes the unique properties of circRNA,  such
as enhanced stability and superior immunological profile, which are important
advantages compared to linear mRNA-based technologies. Supported by the latest
research, the review also evaluates the suitability of in vitro-transcribed
(IVT) and vector-based circRNA platforms for specific targets, including
applications in rare genetic diseases, oncology, and autoimmune disorders.
Finally, it explores why circRNAs are poised to surpass mRNAs as the preferred
RNA format for clinical development, detailing which circRNA technologies are
closest to clinical realization and identifying the key challenges that must be
addressed to bring them to fruition.

"We were honoured to be invited to contribute to the highly esteemed journal
Nature Reviews Genetics. The review offers a comprehensive overview of the
current development of circular RNA and its potential therapeutic applications.
It will hopefully serve as both an important introduction to the field, as well
as a source of valuable insights for researchers, industry professionals and a
general audience alike," says Dr. Thomas Hansen, CTO of Circio. "Following our
pioneering work on the biogenesis and functional role of human circRNA, there
have been a number of essential developments that open up novel therapeutic
approaches to a wide range of indications. This is therefore a timely review
that details where the field currently stands and summarizes the different
potential development avenues for this exciting new modality."

The review was first-authored by Eoghan O'Leary, VP of research at Circio, and
co-authored by Thomas Hansen, CTO at Circio and co-discoverer of circular RNA,
Yanyi Jiang, Graduate student at Aarhus University, Lasse Kristensen, Associate
professor at Aarhus University, and Jørgen Kjems, professor at Aarhus
University.

The article is now available on Nature.com: The therapeutic potential of
circular RNAs | Nature Reviews Genetics (https://www.nature.com/articles/s41576
-024-00806-x)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter - Hunter PR
Phone:+44 7821 255568 (http://tel:+447821255568)
Email: neiljameshunter@gmail.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.